Hanwha Pharma

Hanwha Pharma is a South Korean pharmaceutical company founded in 1976 that focuses on the development and commercialization of therapeutics across several key medical fields. The company is particularly recognized for its leadership in the respiratory sector, anchored by its flagship product Umckamin, an herbal treatment for bronchitis. Beyond respiratory health, Hanwha Pharma maintains a diverse portfolio in cardiovascular, digestive, and musculoskeletal diseases, often collaborating with international partners to license and distribute specialized medicines. The company operates GMP-certified manufacturing facilities in Chuncheon and continues to invest in the development of incrementally modified drugs (IMDs) to enhance patient outcomes. Through its subsidiary Yangji Chemical, the company also maintains capabilities in active pharmaceutical ingredient (API) production. It remains an independent entity, distinct from the Hanwha Group conglomerate.